| Little, Susan |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
NCT04240691: Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care |
|
|
| Completed | N/A | 52 | US | 60-Minutes-For-Health, Time-and-Attention Control Session | University of California, San Diego, Gilead Sciences | Hiv, HIV Infections | 09/22 | 04/24 | | |
| Lo, Janet |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
| Luetkemeyer, Annie |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 128 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
| Guerrero, Mario |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
| Not yet recruiting | 2 | 110 | US | ISS-SBDOH arm | University of California, Los Angeles, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, EtectRX, Inc., National Institute on Minority Health and Health Disparities (NIMHD) | HIV/AIDS, Medication Adherence, Social Determinants of Health (SDOH) | 12/27 | 12/27 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis |
|
|
| Completed | 1 | 24 | Europe, US | CDX-0159, barzolvolimab, Normal saline | Celldex Therapeutics | Prurigo Nodularis | 07/23 | 07/23 | | |
|
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Dwyer, Jay |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Hendrickx, Steven |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/28 | 08/29 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 200 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 12/25 | 06/26 | | |
